

Malaria Disease Drug Pipeline Analysis

<https://marketpublishers.com/r/MF85270F2DDEN.html>

Date: August 2013

Pages: 185

Price: US\$ 1,200.00 (Single User License)

ID: MF85270F2DDEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Malaria. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated with the Malaria disease. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.

Following parameters for each drug profile in development phase are covered in “Malaria Disease Drug Pipeline Analysis” research report:

Drug Profile Overview

Active Indication

Phase of Development

Country for Clinical Trial

Owner / Originator/ Licensee/Collaborator

Administrative Route

Drug Class

Patent Information

Molecular Formula

Pharmacodynamics

Pharmacokinetics

Brand Names

Development Agreements

ATC Codes

Contents

1. DEVELOPMENT PHASE: PRECLINICAL

- 1.1 Overview
- 1.2 Drug Profile

2. DEVELOPMENT PHASE: PHASE-I

- 2.1 Overview
- 2.2 Drug Profile

3. DEVELOPMENT PHASE: PHASE-I/II

- 3.1 Overview
- 3.2 Drug Profile

4. DEVELOPMENT PHASE: PHASE-II

- 4.1 Overview
- 4.2 Drug Profile

5. DEVELOPMENT PHASE: PHASE-III

- 5.1 Overview
- 5.2 Drug Profile

About

GlaxoSmithKline (GSK) is developing a malaria vaccine based on the malarial circumsporozoite (CS) protein. The vaccine consists of an antigenic amino acid sequence from the CS protein of *Plasmodium falciparum* fused with the hepatitis B surface antigen. It attacks the parasite before the blood stage, preventing it from multiplying inside red blood cells. Development originated with SmithKline Beecham which subsequently merged with Glaxo Wellcome to form GlaxoSmithKline. Phase III clinical investigation of the malaria vaccine is underway in infants in several African countries. In addition, a phase II trial in adults is in progress in the US.

GSK has entered into a collaboration with Crucell for the development of a second generation malaria vaccine [see separate profile: Malaria vaccine-Crucell/GlaxoSmithKline]; the collaboration will focus on the development of a vaccine which incorporates GSK's vaccine candidate RTS, S/AS and Crucell's vaccine candidate Ad35-CS.

GlaxoSmithKline and Antigenics (later Agenus) established a licensing agreement in July 2006 that allowed GlaxoSmithKline to use Antigenics' QS-21 (Stimulon®) adjuvant in the development of its RTS,S vaccine. GlaxoSmithKline was to make milestone payments to Antigenics and pay royalties on net sales for a period of 10 years after first commercialisation of the product. The agreement was amended in March 2012, giving GSK further rights to the adjuvant. GlaxoSmithKline paid Agenus a non-refundable fee of \$US9 million. Antigenics was renamed as Agenus in January 2011.

In 2001, a collaboration was set up between GlaxoSmithKline and the Malaria Vaccine Initiative (MVI) to advance the development of RTS,S/AS02A for children in the developing world. MVI's mission is to accelerate the development of malaria vaccines, and will be providing financial support and a collaborative management style to enable the RTS,S programme to progress at a meaningful pace.

In 1991, SmithKline Beecham (later GlaxoSmithKline) licensed MPL® from RibImmunoChem, which was integrated into Corixa in October 1999. Under the terms of the agreement, SmithKline Beecham was granted worldwide exclusive rights to use MPL® adjuvant in vaccines in a number of infectious disease fields. GlaxoSmithKline will pay Corixa transfer payments for supplies of MPL® and, royalties when products developed under the agreement are commercialised. Subsequently, Corixa was acquired by, and merged into GlaxoSmithKline in July 2005.

I would like to order

Product name: Malaria Disease Drug Pipeline Analysis

Product link: <https://marketpublishers.com/r/MF85270F2DDEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF85270F2DDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970